Patient and Physician Global Assessments of Disease Status in Systemic Sclerosis
Open Access
- 6 January 2023
- journal article
- review article
- Published by Wiley in Arthritis Care & Research
- Vol. 75 (7) , 1443-1451
Abstract
Global assessments of disease by both patients and physicians are widely used in clinical studies of systemic sclerosis (SSc). They are commonly secondary end points in randomized controlled trials (RCTs) and are considered important items in composite measures of treatment response. A comprehensive literature review was conducted of the formats, wording, and clinimetric properties of the patient global assessment of disease status (PtGA) and physician global assessment of disease status (PhGA) used in RCTs of SSc. Marked heterogeneity was found in the wording and measurement scales of the global assessments applied in RCTs. These instruments were not developed using rigorous methodology and have not been fully validated. There is a pressing need for standardization and validation of patient and physician global assessment tools in SSc to enable universal application of these measures across RCTs in SSc.Keywords
This publication has 58 references indexed in Scilit:
- Patient Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA and OMERACT StudyThe Journal of Rheumatology, 2011
- Discordance between Patient and Physician Assessments of Disease Severity in Systemic SclerosisThe Journal of Rheumatology, 2010
- The Minimally Important Difference in Clinical Practice for Patient-centered Outcomes Including Health Assessment Questionnaire, Fatigue, Pain, Sleep, Global Visual Analog Scale, and SF-36 in SclerodermaThe Journal of Rheumatology, 2010
- Novel evidence‐based systemic lupus erythematosus responder indexArthritis Care & Research, 2009
- Development of a provisional core set of response measures for clinical trials of systemic sclerosisAnnals of the Rheumatic Diseases, 2007
- European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteriaAnnals of the Rheumatic Diseases, 2003
- A randomized, controlled trial of methotrexate versus placebo in early diffuse sclerodermaArthritis & Rheumatism, 2001
- Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis & Rheumatism, 1995
- A double‐blind randomized controlled trial of ketotifen versus placebo in early diffuse sclerodermaArthritis & Rheumatism, 1991
- 5-fluorouracil in the treatment of scleroderma: a randomised, double blind, placebo controlled international collaborative study.Annals of the Rheumatic Diseases, 1990